Measured by its binding ability in a functional ELISA. Immobilized canine TNFRSF9-His at 10 μg/ml (100 μl/well) can bind rat Fc-TNFSF9, The EC50 of rat Fc-TNFSF9 is 0.26-0.62 μg/ml.

4-1BB Ligand/TNFSF9 Protein, Rat, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 50.9 kDa and the accession number is Q80WE6.

Rat

HEK293 Cells

tumor necrosis factor (ligand) superfamily, member 9

The Rat TNFSF9 (Q80WE6) (Pro106-Gly308) was expressed, fused with Fc region of Human IgG1 at the N-terminus.

> 96 % as determined by SDS-PAGE

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

4-1BB ligand is the high affinity ligand of 4-1BB, also known as CD137L or TNFSF9. It is shown to be a type II surface glycoprotein belonging to the TNF superfamily. Expression of 4-1BBL is restricted to APCs, such as dendritic cells, macrophages, and activated B cells. Members of the TNF-TNF receptor superfamily have been shown to play critical roles in regulating cellular activation, differentiation and apoptosis. Several studies have reported that 4-1BBL/4-1BB interaction provided a co-stimulatory signal to T cells, and increased T cell proliferation and cytokines production. In addition, 4-1BBL is involved in cancers, infectious diseases and autoimmune diseases.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint TargetsImmunotherapyTargeted Therapy